tiprankstipranks
Phreesia (DE:19P)
FRANKFURT:19P
Germany Market

Phreesia (19P) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

19P Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Phreesia
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

19P Stock 12 Month Forecast

Average Price Target

€11.58
▲(20.00% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is €11.58 with a high forecast of €13.72 and a low forecast of €8.58. The average price target represents a 20.00% change from the last price of €9.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","27":"€27","11.25":"€11.25","16.5":"€16.5","21.75":"€21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.724952,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.58042825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€11.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.578095,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,11.25,16.5,21.75,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.455765538461538,9.811531076923076,10.167296615384615,10.523062153846153,10.878827692307691,11.234593230769232,11.590358769230768,11.946124307692308,12.301889846153845,12.657655384615385,13.013420923076923,13.369186461538462,{"y":13.724952,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.290802173076923,9.481604346153846,9.672406519230769,9.863208692307692,10.054010865384615,10.244813038461539,10.435615211538462,10.626417384615385,10.817219557692308,11.008021730769231,11.198823903846154,11.389626076923077,{"y":11.58042825,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.059853461538461,9.019706923076923,8.979560384615384,8.939413846153846,8.899267307692307,8.859120769230769,8.81897423076923,8.778827692307692,8.738681153846153,8.698534615384615,8.658388076923076,8.618241538461538,{"y":8.578095,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€13.72Average Price Target€11.58Lowest Price Target€8.58
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:19P
Canaccord Genuity
Canaccord Genuity
€13.72
Buy
42.23%
Upside
Reiterated
08/11/26
Phreesia (PHR) Gets a Buy from Canaccord Genuity
J.P. Morgan Analyst forecast on DE:19P
J.P. Morgan
J.P. Morgan
€12.01
Hold
24.45%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)
BMO Capital Analyst forecast on DE:19P
BMO Capital
BMO Capital
€12.01
Buy
24.45%
Upside
Reiterated
06/22/26
Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)
Barclays
€8.58
Hold
-11.11%
Downside
Reiterated
06/15/26
Barclays Sticks to Their Hold Rating for Phreesia (PHR)
Truist Financial Analyst forecast on DE:19P
Truist Financial
Truist Financial
Hold
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)
Jefferies Analyst forecast on DE:19P
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€17.16
Buy
77.78%
Upside
Reiterated
05/28/26
Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)
D.A. Davidson Analyst forecast on DE:19P
D.A. Davidson
D.A. Davidson
€12.01
Buy
24.45%
Upside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)
William Blair Analyst forecast on DE:19P
William Blair
William Blair
Buy
Reiterated
05/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)
Citi
€8.58€10.29
Hold
6.67%
Upside
Reiterated
05/28/26
Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi
Wells Fargo Analyst forecast on DE:19P
Wells Fargo
Wells Fargo
€7.72
Hold
-20.00%
Downside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)
Piper Sandler Analyst forecast on DE:19P
Piper Sandler
Piper Sandler
€19.73€10.29
Hold
6.67%
Upside
Downgraded
05/28/26
Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler
Needham
€12.01
Buy
24.45%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)
RBC Capital Analyst forecast on DE:19P
RBC Capital
RBC Capital
€16.3
Buy
68.90%
Upside
Reiterated
05/27/26
RBC Capital Remains a Buy on Phreesia (PHR)
KeyBanc
€12.87€10.29
Buy
6.67%
Upside
Assigned
04/13/26
Phreesia (PHR) Gets a Buy from KeyBanc
Citizens JMP Analyst forecast on DE:19P
Citizens JMP
Citizens JMP
Hold
Downgraded
04/01/26
Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on DE:19P
Canaccord Genuity
Canaccord Genuity
€13.72
Buy
42.23%
Upside
Reiterated
08/11/26
Phreesia (PHR) Gets a Buy from Canaccord Genuity
J.P. Morgan Analyst forecast on DE:19P
J.P. Morgan
J.P. Morgan
€12.01
Hold
24.45%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)
BMO Capital Analyst forecast on DE:19P
BMO Capital
BMO Capital
€12.01
Buy
24.45%
Upside
Reiterated
06/22/26
Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)
Barclays
€8.58
Hold
-11.11%
Downside
Reiterated
06/15/26
Barclays Sticks to Their Hold Rating for Phreesia (PHR)
Truist Financial Analyst forecast on DE:19P
Truist Financial
Truist Financial
Hold
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)
Jefferies Analyst forecast on DE:19P
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€17.16
Buy
77.78%
Upside
Reiterated
05/28/26
Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)
D.A. Davidson Analyst forecast on DE:19P
D.A. Davidson
D.A. Davidson
€12.01
Buy
24.45%
Upside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)
William Blair Analyst forecast on DE:19P
William Blair
William Blair
Buy
Reiterated
05/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)
Citi
€8.58€10.29
Hold
6.67%
Upside
Reiterated
05/28/26
Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi
Wells Fargo Analyst forecast on DE:19P
Wells Fargo
Wells Fargo
€7.72
Hold
-20.00%
Downside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)
Piper Sandler Analyst forecast on DE:19P
Piper Sandler
Piper Sandler
€19.73€10.29
Hold
6.67%
Upside
Downgraded
05/28/26
Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler
Needham
€12.01
Buy
24.45%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)
RBC Capital Analyst forecast on DE:19P
RBC Capital
RBC Capital
€16.3
Buy
68.90%
Upside
Reiterated
05/27/26
RBC Capital Remains a Buy on Phreesia (PHR)
KeyBanc
€12.87€10.29
Buy
6.67%
Upside
Assigned
04/13/26
Phreesia (PHR) Gets a Buy from KeyBanc
Citizens JMP Analyst forecast on DE:19P
Citizens JMP
Citizens JMP
Hold
Downgraded
04/01/26
Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Phreesia

3 Months
John RansomRaymond James
Success Rate
9/16 ratings generated profit
56%
Average Return
+0.33%
Copying John Ransom's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +0.33% per trade.
1 Year
Ryan DanielsWilliam Blair
Success Rate
4/9 ratings generated profit
44%
Average Return
-14.94%
Copying Ryan Daniels's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -14.94% per trade.
2 Years
Ryan DanielsWilliam Blair
Success Rate
4/9 ratings generated profit
44%
Average Return
+1.37%
Copying Ryan Daniels's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +1.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

19P Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
16
17
8
5
1
Buy
3
6
5
3
1
Hold
6
13
12
10
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
36
25
18
5
In the current month, 19P has received 2 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 19P average Analyst price target in the past 3 months is 11.58.
Each month's total comprises the sum of three months' worth of ratings.

19P Financial Forecast

19P Earnings Forecast

Next quarter’s earnings estimate for 19P is €0.07 with a range of <€0.01 to €0.16. The previous quarter’s EPS was €0.04. 19P beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 19P has Performed in-line its overall industry.
Next quarter’s earnings estimate for 19P is €0.07 with a range of <€0.01 to €0.16. The previous quarter’s EPS was €0.04. 19P beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 19P has Performed in-line its overall industry.

19P Sales Forecast

Next quarter’s sales forecast for 19P is €110.78M with a range of €109.01M to €112.38M. The previous quarter’s sales results were €112.39M. 19P beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 19P has Performed in-line its overall industry.
Next quarter’s sales forecast for 19P is €110.78M with a range of €109.01M to €112.38M. The previous quarter’s sales results were €112.39M. 19P beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 19P has Performed in-line its overall industry.

19P Stock Forecast FAQ

What is DE:19P’s average 12-month price target, according to analysts?
Based on analyst ratings, Phreesia’s 12-month average price target is 11.58.
    What is DE:19P’s upside potential, based on the analysts’ average price target?
    Phreesia has 20.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Phreesia a Buy, Sell or Hold?
          Phreesia has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Phreesia’s share price target?
            The average share price target for Phreesia is 11.58. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €13.72 ,and the lowest forecast is €8.58. The average share price target represents 20.00% Increase from the current price of €9.65.
              What do analysts say about Phreesia?
              Phreesia’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Phreesia?
                To buy shares of DE:19P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.